Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VPHM - Viropharma Inc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (105)	7/14/1999 6:21:00 PM
From: baggo	Read Replies (1) \| Respond to of 2557

Mr Harmon, There are lots of Anti-viral drugs on the market. You think this one is special? GGGGGG. Linus Pauling strikes again. Buy some Cold-eze. Regards, Brice

To: scaram(o)uche who wrote (105)	7/14/1999 6:27:00 PM
From: moby_dick	Read Replies (1) \| Respond to of 2557

Richard, with all due respect, you use a lot of "million-dollar words" to try and make your point but it falls way short IMO. Either way you look at it, approval of the existing product is way off into the future. Furthermore, it really only addresses the meningitis issue - not the "common cold" that most "investors" thought they saw today. While the company should indeed be commended with their apparent success against meningitis (although 80% of 21 patients with chronic meningoencephalitis is not a statistically-significant population), a cure for the common cold the product is not! FINALLY, add in the fact that we are beginning to see insiders filing to sell restricted stock does not bode well for the near-to-medium term stock price. JMO though. Moby.